English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/63211
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating co-treatment with dexamethasone

AuthorsPaz-Ares, Luis ; Buesa, J. M.
Issue Date2012
PublisherSpringer
CitationInvestigational New Drugs 30(2): 729-740 (2012)
AbstractPurpose: This study assesses the efficacy, toxicity and pharmacokinetic profile of trabectedin with or without prophylactic dexamethasone co-treatment in patients with recurrent advanced soft tissue sarcoma (STS).
Patients and methods: Patients were randomized to receive trabectedin as a 3-h infusion every 3 weeks with dexamethasone or placebo in the first cycle, with the alternate in the second cycle and with the patient's choice subsequently. Due to toxicity, the randomized design was modified to openlabel to make dexamethasone mandatory and the initial dose (1,650 μg/m 2) was reduced to 1,500 μg/m 2 and then to 1,300 μg/m 2.
Results: Forty-one patients were enrolled and 35 were evaluable for efficacy. One partial response and 18 disease stabilizations were found. The median PFS and OS were 2.1 and 10.2 months, respectively, with the 3- and 6-month PFS rates indicating activity in pretreated STS. Twenty-three and 27 patients developed transient asymptomatic grade 3/4 AST and ALT elevation, respectively, and 21 patients had grade 3/4 neutropenia. Dose reduction from 1,650 μg/m 2 to 1,300 μg/m 2 decreased the incidence of grade 3/4 thrombocytopenia (26% vs. 0%), neutropenia (51% vs. 25%) and AST increase (76% vs. 25% of patients). Four patients died due to drug-related toxicities (3 with placebo). The total body clearance of trabectedin was 28% higher and half-life was 21% lower with dexamethasone compared to placebo, with no differences in volume of distribution.
Conclusions: Trabectedin has confirmed activity in patients with pretreated STS. This study shows that cotreatment with dexamethasone improves the safety of trabectedin by reducing drug-induced hepatotoxicity and myelosuppression. © Springer Science+Business Media, LLC 2010.
URIhttp://hdl.handle.net/10261/63211
DOI10.1007/s10637-010-9561-9
Identifiersdoi: 10.1007/s10637-010-9561-9
issn: 0167-6997
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.